Malarial parasite proteins

Malarial parasite proteins encompass the diverse array of proteins expressed by Plasmodium species, such as P. falciparum and P. vivax, which are essential for the parasite's survival and pathogenesis [1, 3]. These proteins perform critical functions across the complex parasite life cycle, including the invasion of host hepatocytes and erythrocytes, nutrient acquisition via the degradation of host hemoglobin, and evasion of the host immune system through antigenic variation [2, 6]. Key targets within this group include metabolic enzymes like dihydrofolate reductase (DHFR), proteases such as falcipains and plasmepsins, and surface virulence factors like Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) [1, 3]. Antimalarial drugs target these proteins through various mechanisms; for instance, artemisinins act by forming covalent adducts with a wide range of parasite proteins, while quinolines interfere with heme detoxification processes mediated by parasite proteins [7, 8]. The high degree of genetic polymorphism and rapid evolution of these proteins are primary drivers of widespread drug resistance, posing a major challenge to current therapeutic strategies and vaccine development [3, 9].

Other names

Plasmodium proteinsMalarial antigensParasite-derived proteinsPlasmodium falciparum proteins

Drugs targeting malarial parasite proteins operate through several mechanisms: inhibition of essential metabolic enzymes like DHFR and DHPS (antifolates), disruption of heme detoxification in the food vacuole (quinolines), inhibition of mitochondrial electron transport (atovaquone), and the generation of reactive free radicals that form toxic covalent adducts with various parasite proteins and lipids (artemisinins) [1, 7, 8].